Liminatus Pharma, Inc. filed an amendment to its Certificate of Incorporation to effect a 1-for-50 reverse stock split of its common stock, effective August 20, 2026. The action addresses Nasdaq delisting risks related to minimum bid price and market value requirements following the company's transfer from the Nasdaq Global Market to the Nasdaq Capital Market on August 4, 2026. Outstanding shares are expected to decrease from approximately 67.1 million to 1.3 million, with fractional shares rounded up to whole shares without cash payment. The company operates in the biotechnology industry, developing immune-modulating cancer therapies.
